CD34 and Stroke: Most importantly, given no therapy for ischemic-hemorrhagic stroke risk, the identification of cd45- [cd34+/kdr+]EPCs as juvenile protective factors provides key insight into a translational paradigm to attenuate stroke pathogenesis.